INMB Q4 2022 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$35M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$97,000-40.5% YoY

Gross Profit

$97,000100.0% margin

Operating Income

-$6M-5816.5% margin

Net Income

-$6M-6013.4% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

-1.0%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$82M

Total Liabilities

$22M

Stockholders' Equity

$60M

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$97,000	$163,000	-40.5%
Gross Profit	$97,000	$163,000	-40.5%
Operating Income	-$6M	-$9M	+37.5%
Net Income	-$6M	-$10M	+39.7%